NEW YORK, Oct. 13 (GenomeWeb News) - Dutch biotech Galapagos has acquired around 77 percent of BioFocus as part of its deal to buy the company, and will obtain the remaining 24 percent over the coming weeks, a Galapagos official said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.